Koers Bachem Holding AG Swiss Exchange
Aandelen
BANB
CH0012530207
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 618 mln. 685 mln. 635 mln. | Omzet 2025 * | 823 mln. 912 mln. 845 mln. | Marktkapitalisatie | 6,48 mld. 7,18 mld. 6,65 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 127 mln. 141 mln. 130 mln. | Nettowinst (verlies) 2025 * | 160 mln. 177 mln. 164 mln. | EV/omzet 2024 * | 10,4 x |
Nettoliquiditeiten 2024 * | 78,09 mln. 86,56 mln. 80,22 mln. | Nettoschuld 2025 * | 28,4 mln. 31,48 mln. 29,17 mln. | EV/omzet 2025 * | 7,91 x |
K/w-verhouding 2024 * |
51,6
x | K/w-verhouding 2025 * |
40,2
x | Werknemers | 2.006 |
Dividendrendement 2024 * |
1% | Dividendrendement 2025 * |
1,04% | Vrij verhandelbaar | 94,31% |
Recentste transcriptie over Bachem Holding AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 01-01-19 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 01-02-21 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-03 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 25-04-12 |
Director/Board Member | 51 | 13-04-11 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.15% | 18 M€ | +6,77% | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,30% | 46,03 mld. | |
+52,73% | 44,55 mld. | |
+7,15% | 40,8 mld. | |
-5,11% | 28,25 mld. | |
+18,68% | 27,71 mld. | |
-21,92% | 18,82 mld. | |
+14,62% | 13,91 mld. | |
+31,85% | 12,43 mld. | |
-8,77% | 11,06 mld. |